IMMUNEONCO-B
- Country
- 🇭🇰Hong Kong, China
- Ownership
- -
- Established
- 2015-06-18
- Employees
- 150
- Market Cap
- -
- Website
- http://cn.immuneonco.com
- Introduction
Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. is a scientific research-oriented biotechnology company dedicated to developing innovative cancer immunotherapy. The company was incorporated in 2015 and is one of the few biotechnology companies in the world that can systematically utilize innate immunity and adaptive immune systems. By strictly adhering to the “Drug-by-Design” concept and using our R&D platform, we have designed a rich pipeline portfolio, including more than ten innovative drug candidates and eight ongoing clinical projects. Our pipeline is based on the deep and broad asset portfolio of innate immunity, which reflects our deep understanding of cutting-edge tumor biology and immunology, as well as our expertise in turning scientific research into drug candidates.
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
- Conditions
- Advanced Solid TumorAdvanced CholangiocarcinomaAdvanced Lung CancerAdvanced Gastric Carcinoma
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT05805956
- Locations
- 🇨🇳
301 Hospital, Beijing, China
🇨🇳Fudan University Cancer Hospital, Shanghai, China
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
- Conditions
- Breast CancerAdvanced Solid TumorSmall Cell Lung CancerNon-small Cell Lung CancerSquamous Cell Cancer of Head and NeckColorectal Cancer
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05780307
- Locations
- 🇨🇳
Affilated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
- Conditions
- B-cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05771883
IMM40H Phase I Dose Escalation and Expansion
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05549557
Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05235438
- Locations
- 🇨🇳
Henan Cancer Hospital, Henan, China
🇨🇳Sun Yai-Sen Memorial Hospital,Sun Yai-Sen University, Guangzhou, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, China
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05140811
- Locations
- 🇨🇳
The first affiliated hospital of nanchang University, Nanchang, China
🇨🇳Shanghai sixth's hospital, Shanghai, China
🇨🇳Ganzhou People's Hospital, Ganzhou, China
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
- Conditions
- Advanced Breast CancerAdvanced Solid TumorAdvanced Gastric Cancer
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT05076591
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸NEXT Virginia, LLC, Fairfax, Virginia, United States
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04746131
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States